Zainab Al-Taie

Zainab Al-Taie

Auto-generated profile, based on publicly available information

Zainab Al-Taie

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Science Immunology
Verified
Journal Article
Closed access
PCPablo Canales-Herrerias
Pablo Canales-Herrerias
MUMathieu Uzzan
Mathieu Uzzan
ASAkihiro Seki
Akihiro Seki
RCRafael S. Czepielewski
Rafael S. Czepielewski
BVBram Verstockt
Bram Verstockt
SMSaurabh Mehandru
Saurabh Mehandru
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7 + ) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-α4β7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry. In VDZ-treated patients with UC, treatment responders demonstrated reduced intestinal lymphoid aggregate size and follicle organization and a reduction of β7 + IgG + plasmablasts in circulation, as well as IgG + plasma cells and FcγR-dependent signaling in the intestine. GALT targeting represents a previously unappreciated mechanism of action of α4β7-targeted therapies, with major implications for this therapeutic paradigm in UC.

1 July 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
OCOren Cohen
Oren Cohen
MSManuel Sánchez-de-la-Torre
Manuel Sánchez-de-la-Torre
ZAZainab Al-Taie
Zainab Al-Taie
SKSamira Khan
Samira Khan
VKVaishnavi Kundel
Vaishnavi Kundel
NSNeomi A. Shah
Neomi A. Shah
Rationale: Randomized controlled trials of continuous positive airway pressure (CPAP) therapy for cardiovascular disease (CVD) prevention among patients with obstructive sleep apnea (OSA) have been largely neutral. However, given that OSA is a heterogeneous disease, there may be unidentified subgroups demonstrating differential treatment effects. Objectives: We sought to apply a novel data-drive approach to identify nonsleepy OSA subgroups with heterogeneous effects of CPAP on CVD outcomes within the Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome (ISAACC) study. Methods: Participants were randomly partitioned into two datasets. One for training (70%) our machine-learning model and a second (30%) for validation of significant findings. Model-based recursive partitioning was applied to identify subgroups with heterogeneous treatment effects. Survival analysis was conducted to compare treatment (CPAP vs. usual care [UC]) outcomes within subgroups. Results: A total of 1,224 nonsleepy OSA participants were included. Of 55 features entered into our model, only two appeared in the final model (i.e., average OSA event duration and hypercholesterolemia). Among participants at or below the model-derived average event duration threshold (19.5 s), CPAP was protective for a composite of CVD events (training hazard ratio [HR], 0.46; P = 0.002). For those with longer event duration (>19.5 s), an additional split occurred by hypercholesterolemia status. Among participants with longer event duration and hypercholesterolemia, CPAP resulted in more CVD events compared with UC (training HR, 2.24; P = 0.011). The point estimate for this harmful signal was also replicated in the testing dataset (HR, 1.83; P = 0.118). Conclusions: We discovered subgroups of nonsleepy OSA participants within the ISAACC study with heterogeneous effects of CPAP. Among the training dataset, those with longer OSA event duration and hypercholesterolemia had nearly 2.5 times more CVD events with CPAP compared with UC, whereas those with shorter OSA event duration had roughly half the rate of CVD events if randomized to CPAP.

25 October 2024 in Science Immunology
Verified
Journal Article
Closed access
FCFrancesca Cossarini
Francesca Cossarini
JSJoan Shang
Joan Shang
AKAzra Krek
Azra Krek
ZAZainab Al-Taie
Zainab Al-Taie
RHRuixue Hou
Ruixue Hou
SMSaurabh Mehandru
Saurabh Mehandru
Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high-resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. Immunoglobulin A–positive (IgA + ) PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)–treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia.

20 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancesca Cossarini
Francesca Cossarini
JSJoan Shang
Joan Shang
AKAzra Krek
Azra Krek
ZAZainab Al-Taie
Zainab Al-Taie
RHRuixue Hou
Ruixue Hou
SMSaurabh Mehandru
Saurabh Mehandru
Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA + PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary: Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA + plasma cells and systemic inflammation.


5 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
TTTaylor Treacy
Taylor Treacy
RPReginald Pereira
Reginald Pereira
PTPranai Tandon
Pranai Tandon
OCOren Cohen
Oren Cohen
VKVaishnavi Kundel
Vaishnavi Kundel
AMAdam S. Morgenthau
Adam S. Morgenthau
Background: Patients with cardiac sarcoidosis (CS) and mildly impaired left ventricular ejection fraction remain at high risk for sudden cardiac death. However, risk stratification for implantable cardioverter‐defibrillator implantation in this group is needed. We aimed to determine if electrophysiologic study (EPS) may be used as a noninvasive alternative for sudden cardiac death risk stratification. Methods: In this retrospective cohort study, we analyzed patients with CS (aged >18 years) with highly probable or probable sarcoidosis according to the World Association of Sarcoidosis and Other Granulomatous Disorders Sarcoidosis Organ Assessment Instrument, with evidence of late gadolinium enhancement on cardiac magnetic resonance imaging in a pattern consistent with CS and left ventricular ejection fraction ≥40%, who underwent EPS. Results: We identified 101 patients with CS, 15 EPS positive and 86 EPS negative. A higher proportion of patients with an EPS‐positive study was associated with antiarrhythmic therapy ( P= 0.005) and ventricular tachycardia on ECG or Holter monitoring ( P< 0.001). In multivariable analysis, transmural myocardial scarring (odds ratio, 3.78 [95% CI, 1.05–14]; P =0.041) and edema on T2‐weighted cardiac magnetic resonance imaging (odds ratio, 4.75 [95% CI, 1.09–21.2]; P= 0.036) were associated with higher odds of an EPS‐positive study. There was no association between anatomic distribution of scar within left ventricular and right ventricular segments and inducibility on EPS. Conclusions: In patients with CS and mildly impaired left ventricular ejection fraction, we demonstrated that transmural myocardial scarring and edema on T2‐weighted cardiac magnetic resonance imaging are associated with sustained ventricular arrhythmia during EPS, suggesting that noninvasive imaging features may be used as prognostic indicators in patients with CS. Larger, prospective studies are needed to inform implantable cardioverter‐defibrillator implantation guidelines.